55 related articles for article (PubMed ID: 29259349)
1. Pan-cancer analysis reveals multifaceted roles of retrotransposon-fusion RNAs.
Lee B; Park J; Voshall A; Maury E; Kang Y; Kim YJ; Lee JY; Shim HR; Kim HJ; Lee JW; Jung MH; Kim SC; Chu HBK; Kim DW; Kim M; Choi EJ; Hwang OK; Lee HW; Ha K; Choi JK; Kim Y; Choi Y; Park WY; Lee EA
bioRxiv; 2023 Oct; ():. PubMed ID: 37905014
[TBL] [Abstract][Full Text] [Related]
2. Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications.
Dharavath B; Butle A; Chaudhary A; Pal A; Desai S; Chowdhury A; Thorat R; Upadhyay P; Nair S; Dutt A
NPJ Precis Oncol; 2024 Mar; 8(1):63. PubMed ID: 38438481
[TBL] [Abstract][Full Text] [Related]
3. Breaking paradigms: Long non-coding RNAs forming gene fusions with potential implications in cancer.
Sánchez-Marín D; Silva-Cázares MB; Porras-Reyes FI; García-Román R; Campos-Parra AD
Genes Dis; 2024 May; 11(3):101136. PubMed ID: 38292185
[TBL] [Abstract][Full Text] [Related]
4. Non-coding RNAs in cancers with chromosomal rearrangements: the signatures, causes, functions and implications.
Han C; Sun LY; Wang WT; Sun YM; Chen YQ
J Mol Cell Biol; 2019 Oct; 11(10):886-898. PubMed ID: 31361891
[TBL] [Abstract][Full Text] [Related]
5. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
6. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
7. Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?
Bossi P; Siano M; Bergamini C; Cossu Rocca M; Sponghini AP; Giannoccaro M; Tonella L; Paoli A; Marchesi E; Perrone F; Pilotti S; Locati LD; Canevari S; Licitra L; De Cecco L
Dis Markers; 2017; 2017():6870614. PubMed ID: 29259349
[TBL] [Abstract][Full Text] [Related]
8. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
Bossi P; Bergamini C; Siano M; Cossu Rocca M; Sponghini AP; Favales F; Giannoccaro M; Marchesi E; Cortelazzi B; Perrone F; Pilotti S; Locati LD; Licitra L; Canevari S; De Cecco L
Clin Cancer Res; 2016 Aug; 22(15):3961-70. PubMed ID: 26920888
[TBL] [Abstract][Full Text] [Related]
9. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
10. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
12. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H
Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593
[TBL] [Abstract][Full Text] [Related]
13. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Müller T; Braun M; Dietrich D; Aktekin S; Höft S; Kristiansen G; Göke F; Schröck A; Brägelmann J; Held SAE; Bootz F; Brossart P
Oncotarget; 2017 Aug; 8(32):52889-52900. PubMed ID: 28881780
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNAs as Biomarkers in Cancer.
Bolha L; Ravnik-Glavač M; Glavač D
Dis Markers; 2017; 2017():7243968. PubMed ID: 28634418
[TBL] [Abstract][Full Text] [Related]
15. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]